Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies
Alzheimer's & Dementia · 2023
DOI: 10.1002/alz.13090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Kathrin Jahreis und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Induced Pluripotent Stem Cells, Tauopathies, Alzheimer Disease. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Technology R&D Project, National Research Foundation of Korea, Alzheimer Forschung Initiative e.V. (AFI).
Abstract (Originalsprache)
INTRODUCTION Hyperphosphorylation and aggregation of the microtubule‐associated protein tau cause the development of tauopathies, such as Alzheimer's disease and frontotemporal dementia (FTD). We recently uncovered a causal link between constitutive serotonin receptor 7 (5‐HT7R) activity and pathological tau aggregation. Here, we evaluated 5‐HT7R inverse agonists as novel drugs in the treatment of tauopathies. METHODS Based on structural homology, we screened multiple approved drugs for their inverse agonism toward 5‐HT7R. Therapeutic potential was validated using biochemical, pharmacological, microscopic, and behavioral approaches in different cellular models including tau aggregation cell line HEK293 tau bimolecular fluorescence complementation, primary mouse neurons, and human induced pluripotent stem cell–derived neurons carrying an FTD‐associated tau mutation as well as in two mouse models of tauopathy. RESULTS Antipsychotic drug amisulpride is a potent 5‐HT7R inverse agonist. Amisulpride ameliorated tau hyperphosphorylation and aggregation in vitro. It further reduced tau pathology and abrogated memory impairment in mice. DISCUSSION Amisulpride may be a disease‐modifying drug for tauopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Department of Life Sciences, Korea University, Seoul, Republic of Korea.
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
- Department of Nanoengineering, Institute of Quantum Optics, Leibniz University Hannover, Hannover, Germany.
ORCID-Profile: Weilun Sun, Alexander Dityatev, Evgeni Ponimaskin
Förderung
- Korea Health Technology R&D Project
- National Research Foundation of Korea
- Alzheimer Forschung Initiative e.V. (AFI)
- Deutsche Forschungsgemeinschaft (DFG)
Zitieren
APA
Jahreis, K., Brüge, A., Borsdorf, S., Müller, F. E., Sun, W., Jia, S., Kang, D. M., Boesen, N., Shin, S., Lim, S., Koroleva, A., Satała, G., Bojarski, A. J., Rakuša, E., Fink, A., Doblhammer-Reiter, G., Kim, Y. K., Dityatev, A., Ponimaskin, E., & Labus, J. (2023). Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13090
Vancouver
Jahreis K, Brüge A, Borsdorf S, Müller FE, Sun W, Jia S, et al. Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies. Alzheimer's & Dementia. 2023. doi:10.1002/alz.13090
BibTeX
@article{Jahreis2023,
author = {Jahreis, Kathrin and Brüge, Alina and Borsdorf, Saskia and Müller, Franziska E and Sun, Weilun and Jia, Shaobo and Kang, Dong Min and Boesen, Nicolette and Shin, Seulgi and Lim, Sungsu and Koroleva, Anastasia and Satała, Grzegorz and Bojarski, Andrzej J and Rakuša, Elena and Fink, Anne and Doblhammer-Reiter, Gabriele and Kim, Yun Kyung and Dityatev, Alexander and Ponimaskin, Evgeni and Labus, Josephine},
title = {Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies},
journal = {Alzheimer's & Dementia},
year = {2023},
doi = {10.1002/alz.13090}
}
EUVIMED